Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polypharmacy in Parkinson’s disease: risks and benefits with little evidence
Authors
Keywords
Medical treatment, Polypharmacy, Parkinsons's
Journal
JOURNAL OF NEURAL TRANSMISSION
Volume 126, Issue 7, Pages 871-878
Publisher
Springer Science and Business Media LLC
Online
2019-06-21
DOI
10.1007/s00702-019-02026-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: implication for Parkinson neuroprotective therapy
- (2018) Vijaya B. Kumar et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress
- (2017) Lisa D. Coles et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
- (2017) Dilan Athauda et al. LANCET
- Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form
- (2017) Timothy J. Collier et al. NEUROBIOLOGY OF DISEASE
- Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: A meta-analysis
- (2017) Yi Xie et al. NEUROSCIENCE LETTERS
- Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
- (2017) Jose A. Santiago et al. Frontiers in Aging Neuroscience
- L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room
- (2016) Rajib Paul et al. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
- Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson’s Disease: Therapeutic Rationale and Current Status
- (2016) Tara Swart et al. CNS DRUGS
- Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Emily J Henderson et al. LANCET NEUROLOGY
- Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology
- (2016) John P. M. Finberg et al. Frontiers in Pharmacology
- Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients
- (2015) Zhenguang Li et al. EUROPEAN NEUROLOGY
- Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
- (2015) LANCET NEUROLOGY
- Laying the foundations for disease-modifying therapies in PD
- (2015) Patrik Brundin et al. Nature Reviews Neurology
- Depression—risk factor or early symptom in Parkinson disease?
- (2015) Albert F. Leentjens Nature Reviews Neurology
- Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
- (2014) Alisdair McNeill et al. BRAIN
- Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
- (2014) K. Stubendorff et al. BMJ Open
- Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12Deficiency
- (2013) Jameson R. Lam et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Shared dysregulated pathways lead to Parkinson's disease and diabetes
- (2013) Jose A. Santiago et al. TRENDS IN MOLECULAR MEDICINE
- A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease
- (2012) I. H. Richard et al. NEUROLOGY
- Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias
- (2011) Imtiaz Ahmed et al. BRAIN
- Serum Cholesterol and the Progression of Parkinson's Disease: Results from DATATOP
- (2011) Xuemei Huang et al. PLoS One
- Clinical risk-benefit assessment of dopamine agonists
- (2008) J. C. Möller et al. EUROPEAN JOURNAL OF NEUROLOGY
- Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments
- (2008) Elmyra V. Encarnacion et al. EUROPEAN NEUROLOGY
- Role of homocysteine in the treatment of Parkinson's disease
- (2008) Thomas Müller Expert Review of Neurotherapeutics
- A controlled trial of antidepressants in patients with Parkinson disease and depression
- (2008) M. Menza et al. NEUROLOGY
- Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood–brain barrier in a rat brain endothelial cell model
- (2008) Sarah Vautier et al. NEUROSCIENCE LETTERS
- Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists
- (2008) Kathleen M Shannon Nature clinical practice. Neurology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now